Elicio Therapeutics (ELTX), Wednesday announced new data from its Phase 2 AMPLIFY-7P trial, showing that 99 percent of evaluable patients treated with its investigational cancer vaccine, ELI-002 7P, generated strong mKRAS-specific T cell responses. On average, immune responses increased 145-fold from baseline, consistent with results seen in earlier Phase 1 studies.
The company expects final disease-free survival data from the trial in the fourth quarter of 2025.
An independent monitoring committee recently recommended the trial continue without changes, which Elicio views as an encouraging sign of potential efficacy.
ELI-002 is designed to target KRAS mutations present in roughly a quarter of all solid tumors, including pancreatic cancer.
ELTX is currently trading at $12.03, up $0.68 or 5.99 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.